Compare GSK plc (GSK) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares UltraPro QQQ ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while ProShares UltraPro QQQ ETF trades at $81.28 (market cap $38.74B). The key difference: GSK plc is far larger — about 2.4× ProShares UltraPro QQQ ETF's market cap, and GSK plc pays a 3.9% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| GSK | TQQQ | |
|---|---|---|
Market Cap | $91.88B | $38.74B |
Volume | 7,730,529 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $87.22 |
52-Week Low | $43.24 | $37.89 |
Typical Hold Time | 93 Days | 24 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
TQQQ trades at $81.28, down 2.78% on the day, with technical indicators showing a bullish bias despite recent selling pressure. The ETF maintains a strong position near its pivot point of $81, supported by positive moving average signals. Recent news highlights ongoing institutional interest alongside concerns about hidden costs and volatility risks inherent in leveraged ETF structures.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face significant volatility risks amplified by the 3x leverage structure. Key opportunities include exposure to Nasdaq-100 growth, while risks center on expense ratios, financing costs, and potential market corrections that could magnify losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
